Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) and Carisma Therapeutics (NASDAQ:CARM – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.
Insider & Institutional Ownership
89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and target prices for Jazz Pharmaceuticals and Carisma Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jazz Pharmaceuticals | 0 | 1 | 16 | 1 | 3.00 |
| Carisma Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Volatility and Risk
Jazz Pharmaceuticals has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of -9.02, suggesting that its stock price is 1,002% less volatile than the S&P 500.
Profitability
This table compares Jazz Pharmaceuticals and Carisma Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jazz Pharmaceuticals | 20.45% | 33.97% | 13.02% |
| Carisma Therapeutics | -254.28% | N/A | -192.17% |
Valuation and Earnings
This table compares Jazz Pharmaceuticals and Carisma Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jazz Pharmaceuticals | $4.27 billion | 3.66 | -$356.15 million | $14.50 | 16.61 |
| Carisma Therapeutics | $10.77 million | 0.00 | -$60.48 million | $0.73 | 0.00 |
Carisma Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Jazz Pharmaceuticals beats Carisma Therapeutics on 13 of the 15 factors compared between the two stocks.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson’s disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
